Bristol Myers Squibb Co. closed $4.40 below its 52-week high ($61.08), which the company achieved on November 11th.

Cancer-focused CytomX Therapeutics Inc. will lay off 40% of its workforce to help extend its cash into second-quarter 2026, ...

Bristol-Myers Squibb Co (BMY) stock saw a decline, ending the day at $56.57 which represents a decrease of $-0.22 or -0.39% from the prior close of $56.79. The stock opened at $56.34 and touched a low ...

Texas Children’s Global HOPE and Baylor College of Medicine Global Health, with support from the Bristol Myers Squibb Foundation, an independent charitable organization, announced the next front in ...

Bristol Myers Squibb (NYSE:BMY) said it expects to report a Q4 net expense of $18M related to acquired IPRD and licensing ...

These seven blue-chip dividend stocks provide investors a steady stream of passive income and offer promising total return.

The proposed sale, pending congressional approval, includes AIM-120C-8 AMRAAM air-to-air missiles to defend against airborne threats, including drones, 155mm artillery shells, small diameter bombs, ...

Encouraging progress supports near-term focus on lead wholly-owned program, CX-2051 (EpCAM PROBODY® ADC). Initial Phase 1a clinical data in advanced metastatic colorectal cancer (CRC) are anticipated ...

Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will host an Investor Conference Call on Wednesday ...

Nearly 2,000 people have taken part in a groundbreaking trial that aims to help doctors identify more people at risk of ...

The tech company’s deal to release a film on Melania Trump has renewed scrutiny of Jeff Bezos’s efforts to get closer to the ...

Recognizing the increased use of artificial intelligence in the development of new therapies, the U.S. FDA on Monday released ...